Topics

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

2014-08-27 03:21:25 | BioPortfolio

Summary

The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with ADHD; and assess the safety of LY2216684 and any side effects that might be associated with it.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Attention Deficit Hyperactivity Disorder

Intervention

LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559)
Spring Valley
California
United States
91978

Status

Recruiting

Source

Eli Lilly and Company

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:21:25-0400

Clinical Trials [8609 Associated Clinical Trials listed on BioPortfolio]

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

The primary purpose of your child's participation in the study is to determine whether LY2216684 can help pediatric patients with ADHD, and assess the safety of LY2216684 and any side effe...

A Multicenter Study Comparing the Efficacy and Safety of OROS® Methylphenidate HCl, Ritalin® (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) ...

Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA

Investigation of efficacy of high-dose extended-release Methylphenidate in adults with ADHD, compared with a placebo

Further Studies of Attention Deficit Disorder - Residual Type (RT)

The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adu...

A Study of Dex-Methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study will compare the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.

PubMed Articles [5452 Associated PubMed Articles listed on BioPortfolio]

Efficacy and Safety of Tipepidine as Adjunctive Therapy in Children with Attention-Deficit / Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

This study aimed to evaluate the efficacy and safety of tipepidine as an add-on to methylphenidate in drug treatment of Attention-deficit /hyperactivity disorder (ADHD).

White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder.

BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/hyperactivity disorder (ADHD). However, not much is known about its effect on the development of human brain white mat...

The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder.

The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide which regulates social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) i...

Use of placebo in French hospitals: data from polyvalent medicine units.

A placebo drug is defined as a treatment without any specific pharmacological efficacy, that works when the patient thinks to receive an active treatment, through a psychological and physiological mec...

Placebo effects in the neuroendocrine system: conditioning of the oxytocin responses.

Evidence exists that placebo effects may influence hormone secretion. However, only few studies examined placebo effects in the endocrine system, including oxytocin placebo effects. We studied whether...

Medical and Biotech [MESH] Definitions

A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.

A methylphenidate derivative, DOPAMINE UPTAKE INHIBITOR and CENTRAL NERVOUS SYSTEM STIMULANT that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

More From BioPortfolio on "A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder"

Quick Search

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial